Patient Identification

Breyanzi®: CAR T with the broadest eligibility for 2L LBCL patients1
Patient characteristics in the 2L LBCL trials included:
Consider Breyanzi for your patients who are:

In the 3rd line TRANSCEND trial, patients were refractory or relapsed after ≥2 prior therapies, ≥18 years old, ECOG PS 0-1, LVEF ≥40%, CrCl >30 mL/min, ALT ≤5 × ULN.1

Early identification of appropriate patients and early collaboration with a CAR T
cell therapy treatment center are key

* PILOT criteria included ALT/AST.
There were 4 patients (1.5%) with ECOG PS 2.
ALT, alanine transaminase; CAR, chimeric antigen receptor; CrCl, creatinine clearance; DLCO, diffusing capacity for carbon monoxide; ECOG PS, Eastern Cooperative Oncology Group performance status; LVEF, left ventricular ejection fraction; ULN, upper limit of normal.


Breyanzi: A smart option for a broad range of second-line DLBCL patients1
Select a patient profile
CAR T cell therapy 2L patient

Joseph*

  • 58 years old, DLBCL
  • Owns and operates a restaurant with his spouse and is hoping to open a new location
  • Has 2 adult children who recently moved to be closer to their parents
  • Knowledgeable about disease and treatment
  • Highly motivated to undergo treatment

* Hypothetical patient.

Response to prior therapy

First-line therapy

  • Refractory to chemoimmunotherapy

Additional risk factors

  • DLBCL transformed from indolent NHL
  • Elevated LDH

Clinical fitness at second line

2L CAR T patient's fitness levels 2L CAR T patient's fitness levels 2L CAR T patient's fitness levels 2L CAR T patient's fitness levels

CrCl, creatinine clearance; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; LVEF, left ventricular ejection fraction; NHL, non-Hodgkin lymphoma.

CAR T cell therapy 2L patient

Susan*

  • 65 years old, early relapsed DLBCL NOS
  • Office administrator who lives with her spouse
  • Has 1 child, who lives at home and attends the local community college
  • Knowledgeable about disease and treatment
  • Motivated to undergo treatment

* Hypothetical patient.

Response to prior therapy

First-line therapy

  • Underwent chemoimmunotherapy; achieved CR
  • Relapsed at 8 months

Additional risk factors

  • One extranodal site

Clinical fitness at second line

2L CAR T patient's fitness levels 2L CAR T patient's fitness levels 2L CAR T patient's fitness levels

CR, complete response; CrCl, creatinine clearance; DLBCL, diffuse large B-cell lymphoma, ECOG PS, Eastern Cooperative Oncology Group performance status; LVEF, left ventricular ejection fraction; NOS, not otherwise specified.

CAR T cell therapy 2L patient

Frank*

  • 64 years old, HGBCL
  • University professor who lives with his spouse
  • Plays in a band as a hobby with friends
  • Son and daughter-in-law are expecting his first grandchild
  • Knowledgeable about disease and treatment
  • Highly motivated to undergo treatment

* Hypothetical patient.

Response to prior therapy

First-line therapy

  • Refractory to chemoimmunotherapy

Additional risk factors

  • Aggressive disease (HGBCL, double-hit/triple-hit)
  • Deauville score of 4
  • Organ-based comorbidities

Clinical fitness at second line

2L CAR T patient's fitness levels 2L CAR T patient's fitness levels 2L CAR T patient's fitness levels

CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; HGBCL, high-grade B-cell lymphoma; LVEF, left ventricular ejection fraction.

CAR T cell therapy 2L patient

Michael*

  • 79 years old, late relapse DLBCL NOS
  • Retired car salesman who lives with his spouse
  • Attending granddaughter’s upcoming wedding and hopes treatment may help him reach this important milestone
  • Knowledgeable about disease and treatment
  • Moderately motivated to undergo treatment

* Hypothetical patient.

Response to prior therapy

First-line therapy

  • Underwent chemoimmunotherapy; achieved CR
  • Relapsed at 18 months

Additional risk factors

  • One extranodal site, nonbulky disease
  • Ineligible for transplant due to age

Clinical fitness at second line

2L CAR T patient's fitness levels 2L CAR T patient's fitness levels 2L CAR T patient's fitness levels

CR, complete response; CrCl, creatinine clearance, DLCBL, diffuse large B-cell lymphoma, EGOC PS, Eastern Cooperative Oncology Group performance status; LVEF, left ventricular ejection fraction; NOS, not otherwise specified.

Consider Breyanzi for your third-line patients
DLBCL relapsed >12 months
CAR T cell therapy 3L patient

Robin*

  • 56 years old, de novo DLBCL
  • Florist in small city who lives with her spouse
  • Her 3 adult children live nearby
  • Knowledgeable about disease and treatment
  • Motivated to undergo treatment

* Hypothetical patient.

Response to prior therapy

First-line therapy

  • Underwent chemoimmunotherapy; achieved CR
  • Relapsed at 18 months

Second-line therapy

  • Underwent high-dose chemotherapy and ASCT
  • Relapsed after 6 months

Additional risk factors

  • One extranodal site
  • Renal impairment

Clinical fitness at second line

3L CAR T patient's fitness levels 3L CAR T patient's fitness levels 3L CAR T patient's fitness levels

ASCT, autologous stem cell transplant; CR, complete response; CrCl, creatinine clearance; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; LVEF, left ventricular ejection fraction.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.